文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

PRESTIGIO注册研究:多重耐药且经治HIV-1感染者抑制性ART下DNA耐药演变

Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该纵向研究纳入PRESTIGIO注册中23例病毒学抑制的高治疗经验且多重耐药HIV-1感染者,在两个时间点分析HIV-1 DNA耐药演变。结果显示HIV-1 DNA主要耐药突变总体稳定,但NNRTI耐药突变及M184V在特定条件下显著下降。

要点

  • 抑制性ART下HTE MDR感染者HIV-1 DNA耐药总体稳定,但M184V和NNRTI耐药可下降。
  • 无NNRTI压力时NNRTI主要耐药突变数显著减少。
  • 3TC/FTC豁免方案或低突变负荷者M184V下降更明显。

核心结论

  • 在病毒学抑制的HTE MDR感染者中,HIV-1 DNA主要耐药突变在约一年内总体保持不变,但M184V和NNRTI耐药在无相应药物压力下可显著下降。

研究设计与样本

  • 来自PRESTIGIO注册的纵向研究,纳入23例病毒学抑制的HTE MDR感染者,比较两个时间点(T0-T1)的HIV-1 DNA。
  • 采用微滴数字PCR定量HIV-1 DNA,并用NGS(阈值5%)评估耐药,同时评估突变负荷。

主要发现

  • T0时病毒学抑制中位时间3年(IQR 3-5),挽救方案多含多替拉韦(95.7%)和/或达芦那韦(69.6%)。
  • HIV-1 DNA中位水平T0为2588 copies/10^6 CD4+细胞,T1为2322 copies/10^6 CD4+细胞(P=0.831)。
  • HIV-1 DNA中至少≥3类耐药者T0为20例(87.0%),T1为18例(78.2%)(P=0.607)。
  • 接受不含NNRTI方案者(52.2%)NNRTI主要耐药突变数从T0的2(1-3)降至T1的0(0-1)(P=0.027)。
  • PI、NRTI和INSTI主要耐药突变数无显著时间差异;M184V随时间下降,尤其在3TC/FTC豁免方案或T0突变负荷<1000 copies/10^6 CD4+细胞者中。

临床怎么用

  • 对病毒学抑制的HTE MDR感染者,HIV-1 DNA耐药检测可辅助评估耐药存档,但总体耐药谱可能稳定。
  • 无NNRTI压力时NNRTI耐药突变可能减少,提示耐药存档受选择压力影响。
  • M184V在3TC/FTC豁免或低突变负荷者中更易下降,解读DNA耐药时需结合治疗史。

局限性

  • 样本量小(23例),结论需更大研究验证。
  • 随访约一年,长期演变不明确。
  • NGS阈值设为5%,可能遗漏低于阈值的突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to clarify whether resistance detected in HIV-1 DNA might evolve in virologically suppressed highly treatment-experienced (HTE) individuals with multidrug resistance (MDR). METHODS: Twenty-three virologically suppressed HTE MDR individuals from the PRESTIGIO Registry with two longitudinal samples available under virological suppression at two different time points (T0-T1) were analysed. HIV-1 DNA levels were quantified using droplet digital PCR, and resistance was assessed through next-generation sequencing (NGS) set at 5%. Mutational load was also evaluated. RESULTS: At T0, individuals had been virologically suppressed for a median time of 3 years (IQR 3-5) under a salvage regimen, mostly containing dolutegravir (95.7%) and/or darunavir (69.6%). The median HIV-1 DNA level was 2588 copies/106 CD4+ cells at T0 and remained stable at T1 (2322 copies/106 CD4+ cells; P = 0.831). Individuals with at least ≥3-class resistance in HIV-1 DNA were 20 (87.0%) at T0 and 18 (78.2%) at T1 (P = 0.607). In those receiving NNRTI-sparing treatment (52.2%), the number of NNRTI major resistance mutation (MRM) significantly decreased over time (T0, 2 [1-3]; T1, 0 [0-1]; P = 0.027). No significant temporal differences in the number of PI, NRTI and integrase strand transfer inhibitor (INSTI) MRM were found. Specific MRM, such as M184V, decreased over time, particularly in individuals who were receiving a 3TC-/FTC-sparing salvage regimen or with a T0 mutational load of <1000 copies/106 CD4+ cells. CONCLUSIONS: Over a year, HIV-1 DNA MRM generally remained unchanged in suppressed HTE MDR people with HIV (PWH) except for a significant decline in M184V and a reduction of NNRTI resistance in the absence of NNRTI pressure.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Armenia D, Marchegiani G, Spagnuolo V, et al. Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry. J Antimicrob Chemother. 2025. PMID: 40990139. doi:10.1093/jac/dkaf349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。